[go: up one dir, main page]

BRPI0413439A - combinações compreendendo estaurosporinas - Google Patents

combinações compreendendo estaurosporinas

Info

Publication number
BRPI0413439A
BRPI0413439A BRPI0413439-7A BRPI0413439A BRPI0413439A BR PI0413439 A BRPI0413439 A BR PI0413439A BR PI0413439 A BRPI0413439 A BR PI0413439A BR PI0413439 A BRPI0413439 A BR PI0413439A
Authority
BR
Brazil
Prior art keywords
inhibitor
ihda
flt
malignancies
combinations
Prior art date
Application number
BRPI0413439-7A
Other languages
English (en)
Inventor
Peter Wisdom Atadja
Kapil N Bhalla
Pamela Sarah Cohen
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0413439A publication Critical patent/BRPI0413439A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMBINAçõES COMPREENDENDO ESTAUROSPORINAS". A presente invenção refere-se a um método de tratamento das síndromes mieloplásticas, linfomas e leucemias e também de tumores sólidos com uma combinação farmacêutica de um inibidor da FLT-3 cinase e um inibidor da histona deacetilase (IHDA). Refere-se também ao uso de uma combinação farmacêutica de um inibidor da FLT-3 cinase e de um inibidor da histona deacetilase (IHDA) para o tratamento das doenças e malignidades mencionadas acima e ao uso de uma composição farmacêutica para a fabricação de um medicamento para o tratamento dessas doenças e malignidades.
BRPI0413439-7A 2003-08-08 2004-08-06 combinações compreendendo estaurosporinas BRPI0413439A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49382803P 2003-08-08 2003-08-08
PCT/EP2004/008848 WO2005014004A1 (en) 2003-08-08 2004-08-06 Combinations comprising staurosporines

Publications (1)

Publication Number Publication Date
BRPI0413439A true BRPI0413439A (pt) 2006-10-17

Family

ID=34135288

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413439-7A BRPI0413439A (pt) 2003-08-08 2004-08-06 combinações compreendendo estaurosporinas

Country Status (9)

Country Link
US (1) US20070191338A1 (pt)
EP (2) EP1653973A1 (pt)
JP (1) JP2007501774A (pt)
CN (1) CN100536850C (pt)
AU (1) AU2004262927B2 (pt)
BR (1) BRPI0413439A (pt)
CA (1) CA2533861A1 (pt)
MX (1) MXPA06001524A (pt)
WO (1) WO2005014004A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006122319A2 (en) 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
CN101237873A (zh) * 2005-08-09 2008-08-06 美因茨约翰内斯古滕贝格大学 用于治疗非小细胞肺癌的星形孢菌素衍生物
WO2007030455A2 (en) * 2005-09-07 2007-03-15 Novartis Ag Mutations and polymorphisms of hdac10
GB0522932D0 (en) * 2005-11-10 2005-12-21 Univ Southampton PKC412 in treatment of atypical chronic myeloid leukemia
GB0612542D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Combinations comprising staurosporines
CN102036955B (zh) 2008-03-26 2013-03-27 诺瓦提斯公司 脱乙酰酶b的异羟肟酸盐为基础的抑制剂
US20110053925A1 (en) * 2009-08-28 2011-03-03 Novartis Ag Hydroxamate-Based Inhibitors of Deacetylases
CN102101866A (zh) * 2010-11-04 2011-06-22 中国海洋大学 十字孢碱卤代衍生物及其制备方法和应用
CA2878873C (en) 2012-07-13 2018-08-21 Turun Yliopisto A pharmaceutical combination including a histone deacetylase 4 (hdac4) silencing agent for treating cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62220196A (ja) 1986-03-20 1987-09-28 Kyowa Hakko Kogyo Co Ltd 新規物質ｕｃｎ―０１
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
SK75289A3 (en) 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
GB8803048D0 (en) 1988-02-10 1988-03-09 Hoffmann La Roche Substituted pyrroles
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
CA2046801C (en) 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
AU2866992A (en) 1991-10-10 1993-05-03 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
EP0575955B1 (en) 1992-06-22 1999-09-15 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
PH30300A (en) 1993-05-07 1997-01-20 Ciba Geigy Ag Polycyclic compounds and processes for the preparation thereof
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
CA2137203C (en) 1993-12-07 2006-11-28 William Francis Heath Jr. Protein kinase c inhibitors
GB9325395D0 (en) 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
AU2565795A (en) 1994-06-01 1995-12-21 Ciba-Geigy Ag Carbazole derivatives as agents against multi-drug resistance
AU2565995A (en) 1994-06-01 1995-12-21 Ciba-Geigy Ag Polycyclic lactam derivatives for sensitizing multidrug-resistant cells to antitumour agents
EP0711557A1 (de) 1994-11-09 1996-05-15 Ciba-Geigy Ag Pharmazeutische Formulierungsgrundlage
EP0733358A3 (de) 1995-03-21 1998-05-20 Novartis AG Intravenös applizierbare Nanosuspensionen
NL1003692C2 (nl) 1996-07-26 1998-01-28 Stork Protecon Langen Bv Inrichting voor het afscheiden van vleesmassa van van vleesresten voorziene botten.
CO4940430A1 (es) 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
DE19744676A1 (de) * 1997-10-10 1999-04-15 Forschungszentrum Borstel Zent Kombinationspräparate für die Therapie von Tumoren
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AR035885A1 (es) * 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
DE60213842T2 (de) * 2001-10-30 2007-09-06 Novartis Ag Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
AU2004230889B2 (en) * 2003-04-07 2008-03-13 Pharmacyclics Llc Hydroxamates as therapeutic agents
MXPA05012464A (es) * 2003-05-21 2006-01-30 Novartis Ag Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.

Also Published As

Publication number Publication date
JP2007501774A (ja) 2007-02-01
MXPA06001524A (es) 2006-05-15
CN1832747A (zh) 2006-09-13
CA2533861A1 (en) 2005-02-17
CN100536850C (zh) 2009-09-09
EP2305265A1 (en) 2011-04-06
AU2004262927A1 (en) 2005-02-17
AU2004262927B2 (en) 2008-05-22
EP1653973A1 (en) 2006-05-10
WO2005014004A1 (en) 2005-02-17
US20070191338A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
IL260127B (en) mek inhibitors and methods of using them
BRPI0413439A (pt) combinações compreendendo estaurosporinas
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BR0115531A (pt) Tratamento de mucosites
CA2414967A1 (en) Valproic acid and derivatives thereof as histone deacetylase inhibitors
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
ATE408601T1 (de) Fredericamycin-derivate
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
CY1109229T1 (el) Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BRPI0507198A (pt) derivados de bisariluréia
BR0315580A (pt) Derivados de metileno uréia
EA200500782A1 (ru) Лечение геморрагического шока
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
WO2007147613A3 (en) Combinations comprising staurosprorines
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
TW200510367A (en) Novel lapachone compounds, their preparation, and the use thereof
BR9702200A (pt) Compostos bicíclicos-aromáticos composição farmacéutica composição cosmética e utilização de uma composição cosmética
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
NO20064753L (no) Kombinasjonsterapi
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
NO20021437D0 (no) Fremgangsmate til forebyggelse av kolorektal kreft
EA202190753A1 (ru) Состав, содержащий озонированное масло, для лечения опухоли

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2266 DE 10/06/2014.